The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
Sign Up to like & getrecommendations! Published in 2022 at "Clinics and research in hepatology and gastroenterology"
DOI: 10.1016/j.clinre.2022.101922
Abstract: PURPOSE - The liver regulates lipid metabolism. Decreasing mTOR (mechanistic target of rapamycin complex 1) and enhancing AMPK (AMP-activated protein kinase) help degrade hepatic diet-induced accumulated lipids. Therefore, the glucagon-like peptide type 1 receptor agonist… read more here.
Keywords: effects semaglutide; obese mice; mtorc1 ampk; receptor agonist ... See more keywords